Whirly lollipop on orange background.

Histogenics (HSGX) may finally deliver an engineered cartilage that can make damaged knees good again. There are a range of new alternatives being developed but the positioning of Histogenics and their “NeoCart” is encouraging. They are enrolling patients for a Phase 3 trial for knee defects. [See the HSGX IPO roadshow slides for the full story.]

At the $14 mid-point of the range and 11.5M shares outstanding the market capitalization would be $161M. It’s important to note that a partner, Intrexon (NYSE: XON), wants to purchase up to $15M in the . . .

Want the rest of the article?

Please login or join us as a member to view our complete content!